🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Akebia Plummets on Late-Stage Study Failure

Published 2020-09-03, 01:37 p/m
© Reuters.
AMGN
-
AKBA
-

By Christiana Sciaudone

Investing.com --  Akebia Therapeutics (NASDAQ:AKBA) plummeted 73% to $2.70 after saying its experimental drug failed to meet the main safety goal in a late-stage trial of patients with anemia due to chronic kidney disease and not undergoing dialysis. 

Earlier this year, Akebia had reported positive trial data for the drug in patients with chronic kidney disease on dialysis. The more recent study evaluated the efficacy and safety of Akebia's treatment, vadadustat, versus Amgen (NASDAQ:AMGN)'s darbepoetin alfa.

Vadadustat failed to meet the safety goal when compared with time to first occurrence of major adverse cardiovascular events. The drug achieved the main goal and secondary goal on efficacy.  

Needham analyst Chad Messer maintained a buy rating on the company, setting a price target of $10. He expects Akebia Therapeutics to post a loss per share of 47 cents for the third quarter, TipRanks reported. 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.